Abstract
Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
| Original language | English (US) |
|---|---|
| Article number | 943409 |
| Journal | Mediators of Inflammation |
| Volume | 2013 |
| DOIs | |
| State | Published - 2013 |
Fingerprint
ASJC Scopus subject areas
- Cell Biology
- Immunology
Cite this
Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. / Agrawal, Shivi; Joshi, Malav; Christoforidis, John B.
In: Mediators of Inflammation, Vol. 2013, 943409, 2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy
AU - Agrawal, Shivi
AU - Joshi, Malav
AU - Christoforidis, John B
PY - 2013
Y1 - 2013
N2 - Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
AB - Vascular endothelial growth factor (VEGF) is a potent promoter of angiogenesis involved in a wide variety of physiologic processes. Intravitreal injections targeting VEGF have transformed the treatment of neovascular retinal diseases. Currently, there are four anti-VEGF agents in use: bevacizumab, ranibizumab, pegaptanib, and aflibercept. The success and frequency of anti-VEGF therapy have made the ocular safety profile of these agents of vital importance. This paper focuses on sterile endophthalmitis. In this paper, we compare the incidences of posttreatment sterile endophthalmitis among the four agents, review the mechanism of actions, and discuss the most prevalent hypotheses leading to sterile endophthalmitis.
UR - http://www.scopus.com/inward/record.url?scp=84888994584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888994584&partnerID=8YFLogxK
U2 - 10.1155/2013/943409
DO - 10.1155/2013/943409
M3 - Article
C2 - 24307762
AN - SCOPUS:84888994584
VL - 2013
JO - Mediators of Inflammation
JF - Mediators of Inflammation
SN - 0962-9351
M1 - 943409
ER -